583 related articles for article (PubMed ID: 24738701)
1. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis.
Alisi A; Bedogni G; Baviera G; Giorgio V; Porro E; Paris C; Giammaria P; Reali L; Anania F; Nobili V
Aliment Pharmacol Ther; 2014 Jun; 39(11):1276-85. PubMed ID: 24738701
[TBL] [Abstract][Full Text] [Related]
2. Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment.
Miccheli A; Capuani G; Marini F; Tomassini A; Praticò G; Ceccarelli S; Gnani D; Baviera G; Alisi A; Putignani L; Nobili V
Int J Obes (Lond); 2015 Jul; 39(7):1118-25. PubMed ID: 25809828
[TBL] [Abstract][Full Text] [Related]
3. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.
Nobili V; Alisi A; Della Corte C; Risé P; Galli C; Agostoni C; Bedogni G
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1066-70. PubMed ID: 23220074
[TBL] [Abstract][Full Text] [Related]
4. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.
Nobili V; Bedogni G; Alisi A; Pietrobattista A; Risé P; Galli C; Agostoni C
Arch Dis Child; 2011 Apr; 96(4):350-3. PubMed ID: 21233083
[TBL] [Abstract][Full Text] [Related]
5. A randomised placebo controlled trial of VSL#3
Chong PL; Laight D; Aspinall RJ; Higginson A; Cummings MH
BMC Gastroenterol; 2021 Apr; 21(1):144. PubMed ID: 33794784
[TBL] [Abstract][Full Text] [Related]
6. Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial.
Jones RB; Alderete TL; Martin AA; Geary BA; Hwang DH; Palmer SL; Goran MI
Pediatr Obes; 2018 Nov; 13(11):705-714. PubMed ID: 29493105
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
[TBL] [Abstract][Full Text] [Related]
8. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance and exercise capacity in male children and adolescents with non-alcholic fatty liver disease.
Manco M; Giordano U; Turchetta A; Fruhwirth R; Ancinelli M; Marcellini M; Nobili V
Acta Diabetol; 2009 Jun; 46(2):97-104. PubMed ID: 18839055
[TBL] [Abstract][Full Text] [Related]
10. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
[TBL] [Abstract][Full Text] [Related]
11. Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children.
Yoo J; Lee S; Kim K; Yoo S; Sung E; Yim J
Diabetes Res Clin Pract; 2008 Sep; 81(3):321-6. PubMed ID: 18571268
[TBL] [Abstract][Full Text] [Related]
12. Hepatic steatosis in obese Chinese children.
Chan DF; Li AM; Chu WC; Chan MH; Wong EM; Liu EK; Chan IH; Yin J; Lam CW; Fok TF; Nelson EA
Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1257-63. PubMed ID: 15278103
[TBL] [Abstract][Full Text] [Related]
13. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.
Ma YY; Li L; Yu CH; Shen Z; Chen LH; Li YM
World J Gastroenterol; 2013 Oct; 19(40):6911-8. PubMed ID: 24187469
[TBL] [Abstract][Full Text] [Related]
14. The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents.
Ciba I; Widhalm K
Acta Paediatr; 2007 Jan; 96(1):109-12. PubMed ID: 17187615
[TBL] [Abstract][Full Text] [Related]
15. Predictors of non-alcoholic fatty liver disease in obese children.
Sartorio A; Del Col A; Agosti F; Mazzilli G; Bellentani S; Tiribelli C; Bedogni G
Eur J Clin Nutr; 2007 Jul; 61(7):877-83. PubMed ID: 17151586
[TBL] [Abstract][Full Text] [Related]
16. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children.
Wang CL; Liang L; Fu JF; Zou CC; Hong F; Xue JZ; Lu JR; Wu XM
World J Gastroenterol; 2008 Mar; 14(10):1598-602. PubMed ID: 18330955
[TBL] [Abstract][Full Text] [Related]
17. Carotid intima-media thickness and flow-mediated dilation in obese children with non-alcoholic fatty liver disease.
Torun E; Aydın S; Gökçe S; Özgen İT; Donmez T; Cesur Y
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():92-8. PubMed ID: 25910377
[TBL] [Abstract][Full Text] [Related]
18. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents.
Fu CC; Chen MC; Li YM; Liu TT; Wang LY
Ann Acad Med Singap; 2009 Jan; 38(1):15-7. PubMed ID: 19221666
[TBL] [Abstract][Full Text] [Related]
19. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Albanian overweight children.
Kodhelaj K; Resuli B; Petrela E; Malaj V; Jaze H
Minerva Pediatr; 2014 Feb; 66(1):23-30. PubMed ID: 24608579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
